Instituto Alexander Fleming

Caba CP1426ANZ

1 studies enrolling now · 3 studies all time

What they study most

Advanced Melanoma, HER2-Positive Primary Breast Cancer, Locally Advanced or Unresectable Metastatic Breast Cancer, Residual Invasive Breast Cancer, Stage IV Breast Cancer

Studies at this site

• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy — Running, not enrolling